Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Bioais reports positive results re multiple sclerosis

Bioais has reported positive results from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in a preclinical rodent model of multiple sclerosis....

| By Kelley Gipson

Rallybio to go public in $100M IPO

Less than four years after a team of former Alexion Pharmaceuticals executives launched a startup to develop new therapies for severe and rare disorders, their...

| By Kelley Gipson

Sosei and InveniAI in drug discovery collaboration

InveniAI andi Sosei Group have announced a new R&D collaboration. The collaboration will combine InveniAI’s AI-powered platform, AlphaMeld®, for target discovery with Sosei Heptares’ G-protein...

| By Kelley Gipson

UConn plan would promote research and startups

A proposal authorizing $47 million in bond funds over five years for what UConn officials have termed “innovation faculty hires” was added to a bonding...

| By Kelley Gipson

Executives named at Hyperfine, Bioasis

Bioasis, which is developing iproprietary platform technology for the delivery of therapeutics across the blood-brain barrier, has announced the appointment of Dave Jenkins as Chief Financial...

| By Kelley Gipson

Moving to CT, Enko focuses on pest control

Jacqueline Heard, founder and CEO of Enko, decided to move the company away from Boston to a 91,000-square-foot facility in Mystic, CT. “We don’t see any...

| By Kelley Gipson

Bioasis reports research and funding agreements

Bioasis Technologies has announced a research collaboration with Oxyrane UK Ltd. The collaboration will focus on combining the two companies’ platform technologies to deliver an undisclosed...

| By Kelley Gipson

Vanessa registers antidiarrheal investigational drug

Vanessa Biotech has registered VR-AD-1005, a novel antidiarrheal investigational drug, with the Pan African Clinical Trials Registry system. The drug will be studied for the innovative...